AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29641737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26944107 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter measurement in patients with pathology (Group I)
Number of subjects: 100
Study 26944107 — intervention group
Group type: COMPARATOR
Intervention: Optic nerve sheath diameter measurement in patients without pathology (Group II)
Number of subjects: 100
Study 26944107 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of midline shift using ONSD measurement
Number of subjects: 100
Study 25586124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg · kg(‐1) over 3 min
Number of subjects: 230
Study 25586124 — intervention group
Group type: COMPARATOR
Intervention: No propofol (control group)
Number of subjects: 230
Study 23724940 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied tension with legs crossed (N=131)
Number of subjects: 404
Study 23724940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard applied tension (N=133)
Number of subjects: 404
Study 23724940 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=140)
Number of subjects: 404
Study 20823898 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B1 (dried and crushed whole berries)
Number of subjects: 10
Study 20823898 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B2 (supercritical fluid CO2-extracted oil-free berries)
Number of subjects: 10
Study 20823898 — intervention group
Group type: COMPARATOR
Intervention: Meal A (control)
Number of subjects: 10
Study 18972900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol spray (Mar plus)
Number of subjects: 128
Study 18972900 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 128
Study 16634955 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse alone (Regimen A)
Number of subjects: 120
Study 16634955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse preceded by SLS-containing slurry (Regimen B)
Number of subjects: 120
Study 16634955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse preceded by SLS-containing dentifrice (Regimen C)
Number of subjects: 120
Study 12807299 — intervention group
Group type: EXPERIMENTAL
Intervention: Deer velvet
Number of subjects: 32
Study 12807299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11109181 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary chemotherapy
Number of subjects: 87
Study 11109181 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based chemotherapy
Number of subjects: 87
Study 8941405 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/wk
Number of subjects: 26
Study 8941405 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2/wk
Number of subjects: 26
Study 1604414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pulse methotrexate (MTX, 5‐7.5mg/week)
Number of subjects: 51
Study 1604414 — intervention group
Group type: COMPARATOR
Intervention: Other DMARDs (bucillamine, D‐penicillamine, salazopyrin, auranofin, lobenzarit)
Number of subjects: 51
Study 4055545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg tid (open study)
Number of subjects: 70
Study 4055545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg bd (comparative study)
Number of subjects: 70
Study 4055545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg tid (comparative study)
Number of subjects: 70
Study 4055545 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg tid (comparative study)
Number of subjects: 70
Study 30747025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter combined with dinoprostone gel (0.5 mg) for 12 hours followed by oxytocin
Number of subjects: 110
Study 30747025 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley catheter alone
Number of subjects: 110
Study 30747025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 28373691 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (MMP inhibitor), dosage and duration not specified
Number of subjects: 0
Study 28373691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26668010 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol responses
Number of subjects: 120
Study 26668010 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal cortisol levels
Number of subjects: 120
Study 26668010 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 120
Study 25149295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-L polyethylene glycol and four tablets of bisacodyl with 90 mL of Iopamidol on the same day as CTC examination (group 1)
Number of subjects: 52
Study 25149295 — intervention group
Group type: COMPARATOR
Intervention: Standard 'iodine-only' preparation, consisting of 180 mL of Iopamidol the day before the examination (group 2)
Number of subjects: 52
Study 23123071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidal neurostimulation
Number of subjects: 40
Study 23123071 — intervention group
Group type: COMPARATOR
Intervention: Sham neurostimulation
Number of subjects: 40
Study 20008774 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Glycerol monolaurate (GML) gel
Number of subjects: 36
Study 20008774 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Glycerol monolaurate (GML) gel
Number of subjects: 36
Study 20008774 — intervention group
Group type: COMPARATOR
Intervention: 0% Control gel
Number of subjects: 36
Study 20008774 — intervention group
Group type: COMPARATOR
Intervention: Control and GML gels
Number of subjects: 36
Study 18957013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal heparin (specifically low-molecular weight heparin)
Number of subjects: 0
Study 18957013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal heparin
Number of subjects: 0
Study 15777683 — intervention group
Group type: EXPERIMENTAL
Intervention: 6007C > T polymorphism (TT vs. CC)
Number of subjects: 1232
Study 15777683 — intervention group
Group type: EXPERIMENTAL
Intervention: 6007C > T polymorphism (CT vs. CC)
Number of subjects: 1232
Study 12456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (prednisolone) + amoxicillin for 14 days, then amoxicillin for 14 more days
Number of subjects: 144
Study 12456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (prednisolone) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Number of subjects: 144
Study 12456902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for steroid) + amoxicillin for 14 days, then amoxicillin for 14 more days
Number of subjects: 144
Study 12456902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for steroid) + amoxicillin for 14 days, then placebo for amoxicillin for 14 more days
Number of subjects: 144
Study 12456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid + amoxicillin
Number of subjects: 144
Study 12456902 — intervention group
Group type: COMPARATOR
Intervention: Placebo + amoxicillin
Number of subjects: 144
Study 10651262 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 16 weeks
Number of subjects: 27
Study 10651262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7734716 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL855 protocol consisting of vincristine, prednisolone, cyclophosphamide, doxorubicin, high-dose methotrexate (HD-MTX), mercaptopurine, cytarabine, CNS prophylaxis with intrathecal MTX and hydrocortisone.
Number of subjects: 69
Study 7734716 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL890 protocol with asparaginase and VP-16 added in the consolidation-maintenance phase for advanced-stage lymphoblastic lymphoma.
Number of subjects: 69
Study 7734716 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL890 protocol for advanced-stage lymphoblastic lymphoma.
Number of subjects: 69
Study 2894175 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 62
Study 2894175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 62
Study 2894175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after switching from clorazepate or lorazepam)
Number of subjects: 62
Study 31906339 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA:DHA supplementation (2:1 ratio)
Number of subjects: 21
Study 31906339 — intervention group
Group type: COMPARATOR
Intervention: MCT-S (control)
Number of subjects: 21
Study 29880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice or three times 100 mg aspirin daily dosing
Number of subjects: 300
Study 29880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term persistence of superior biochemical efficacy with multiple dosing
Number of subjects: 300
Study 29880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TXB2
Number of subjects: 300
Study 29880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary phase results
Number of subjects: 300
Study 28066978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 188
Study 28066978 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 188
Study 28066978 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST
Number of subjects: 188
Study 28066978 — intervention group
Group type: EXPERIMENTAL
Intervention: mRECIST
Number of subjects: 188
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interdialytic period (LIDP)
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: First pre-HD period of the week
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycardia
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus arrest
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-degree atrioventricular block
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (VT)
Number of subjects: 50
Study 26111801 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset paroxysmal atrial fibrillation
Number of subjects: 50
Study 23317096 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open flap debridement (OFD)
Number of subjects: 72
Study 23317096 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) with open flap debridement (OFD)
Number of subjects: 72
Study 23317096 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 72
Study 21353483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Herpes Simplex Virus type 1 (HSV‐1)
Number of subjects: 1308
Study 21353483 — intervention group
Group type: COMPARATOR
Intervention: Exposure to Herpes Simplex Virus type 2 (HSV‐2)
Number of subjects: 1308
Study 21353483 — intervention group
Group type: COMPARATOR
Intervention: Exposure to Cytomegalovirus (CMV)
Number of subjects: 1308
Study 21353483 — intervention group
Group type: COMPARATOR
Intervention: Exposure to Toxoplasma gondii (T gondii)
Number of subjects: 1308
Study 18362499 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 2 years
Number of subjects: 64
Study 22011460 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil capsules (1720 mg DHA and 600 mg EPA daily)
Number of subjects: 391
Study 22011460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 391
Study 16108295 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 40
Study 16108295 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 40
Study 12376165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (triphasic OCs)
Number of subjects: 7
Study 12376165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9669832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotahaler
Number of subjects: 20
Study 9669832 — intervention group
Group type: COMPARATOR
Intervention: MDI with spacer
Number of subjects: 20
Study 9669832 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20
Study 9669832 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol inhaled as a microfine powder
Number of subjects: 20
Study 8148121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal strategy training
Number of subjects: 0
Study 8148121 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution training
Number of subjects: 0
Study 8148121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehearsal and attribution training
Number of subjects: 0
Study 8148121 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study 3410667 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA alone
Number of subjects: 70
Study 3410667 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA + DTIC
Number of subjects: 70
Study 12145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy with ribavirin
Number of subjects: 103
Study 12145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated therapy
Number of subjects: 103
Study 12145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated combination therapy with high dose ribavirin
Number of subjects: 103
Study 12145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained responders regardless of therapy
Number of subjects: 103
Study 12145664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated combination therapy
Number of subjects: 103
Study 30517482 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite bovine bone graft (Biomaterial Group)
Number of subjects: 40
Study 30517482 — intervention group
Group type: COMPARATOR
Intervention: Blood clot (Control Group)
Number of subjects: 40
Study 27041837 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) + demineralized freeze dried bone graft (DFDBA) with open flap debridement (OFD)
Number of subjects: 30
Study 27041837 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with open flap debridement (OFD)
Number of subjects: 30
Study 27041837 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 30
Study 24786931 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg + MTX
Number of subjects: 592
Study 24786931 — intervention group
Group type: COMPARATOR
Intervention: IV placebo + MTX
Number of subjects: 592
Study 22246577 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with major PVMD
Number of subjects: 157
Study 22246577 — intervention group
Group type: COMPARATOR
Intervention: Women without major PVMD
Number of subjects: 157
Study 21961365 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique of cesarean-hysterectomy (hypogastric artery ligation before removal of uterus)
Number of subjects: 86
Study 21961365 — intervention group
Group type: COMPARATOR
Intervention: Usual technique of cesarean-hysterectomy
Number of subjects: 86
Study 18549694 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 446
Study 15655049 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐interferon (3 MU thrice weekly) + ribavirin (1000‐1200 mg/day) for 48 weeks
Number of subjects: 98
Study 15655049 — intervention group
Group type: COMPARATOR
Intervention: No treatment (current standard management)
Number of subjects: 98
Study 12369033 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (0.2 mL 1%) by jet injector
Number of subjects: 50
Study 12369033 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic with a sham injection
Number of subjects: 50
Study 10201102 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 4
Study 10201102 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-out
Number of subjects: 4
Study 10201102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7598778 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangle-shaped hydrocolloid border dressing
Number of subjects: 103
Study 7598778 — intervention group
Group type: COMPARATOR
Intervention: Oval shape hydrocolloid dressing
Number of subjects: 103
Study 1977029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 180
Study 1977029 — intervention group
Group type: COMPARATOR
Intervention: Conventional Schwarz vaccine
Number of subjects: 180
Study 263481 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 210
Study 263481 — intervention group
Group type: COMPARATOR
Intervention: Personal letter
Number of subjects: 210
Study 263481 — intervention group
Group type: COMPARATOR
Intervention: Telephone call
Number of subjects: 210
Study 31296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1083
Study 31296289 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1083
Study 31296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 1083
Study 28323627 — intervention group
Group type: EXPERIMENTAL
Intervention: CCXG injection (100 mL, intravenous drips, 3 times a day)
Number of subjects: 55
Study 28323627 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mL of 10% normal saline injection, 3 times a day)
Number of subjects: 55
Study 26040478 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg administered intravaginally 10 and 4 hours before IUC insertion attempt.
Number of subjects: 100
Study 26040478 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravaginally 10 and 4 hours before IUC insertion attempt.
Number of subjects: 100
Study 26040478 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg administered intravaginally.
Number of subjects: 100
Study 26040478 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravaginally.
Number of subjects: 100
Study 23549122 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 90
Study 23549122 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration (ilioinguinal nerve block and wound infiltration)
Number of subjects: 90
Study 23549122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22035998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus functional analytic psychotherapy (FAP) and acceptance and commitment therapy (ACT)
Number of subjects: 303
Study 22035998 — intervention group
Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 303
Study 19796802 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 56
Study 19796802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 56
Study 19796802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Gabapentin + Nortriptyline)
Number of subjects: 56
Study 19796802 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment vs Gabapentin
Number of subjects: 56
Study 19796802 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment vs Nortriptyline
Number of subjects: 56
Study 16966563 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 12752353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Number of subjects: 14
Study 12752353 — intervention group
Group type: COMPARATOR
Intervention: Tablets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Number of subjects: 14
Study 11078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) in obese subjects
Number of subjects: 41
Study 11078989 — intervention group
Group type: COMPARATOR
Intervention: Oral fat load (OFLT) in healthy controls
Number of subjects: 41
Study 11078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) at 0700 h (diurnal test)
Number of subjects: 41
Study 11078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load (OFLT) at 2200 h (nocturnal test)
Number of subjects: 41
Study 11078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline insulin concentrations in obese subjects
Number of subjects: 41
Study 11078989 — intervention group
Group type: COMPARATOR
Intervention: Baseline insulin concentrations in healthy controls
Number of subjects: 41
Study 8791965 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 12
Study 8791965 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily
Number of subjects: 12
Study 8791965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1637562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream preparations of triamcinolone acetonide and clobetasol propionate
Number of subjects: 24
Study 1637562 — intervention group
Group type: COMPARATOR
Intervention: Ointment preparations of triamcinolone acetonide and clobetasol propionate
Number of subjects: 24
Study 6712870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 16
Study 6712870 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg daily)
Number of subjects: 16
Study 6712870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29696061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel vaginal cream (5 grams) every night for 8 weeks
Number of subjects: 60
Study 29696061 — intervention group
Group type: COMPARATOR
Intervention: Placebo every night for 8 weeks
Number of subjects: 60
Study 29696061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel vaginal cream
Number of subjects: 60
Study 29696061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27295865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM oleic acid
Number of subjects: 11
Study 27295865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM linoleic acid
Number of subjects: 11
Study 27295865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM stearic acid
Number of subjects: 11
Study 27295865 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose followed by free fatty acids
Number of subjects: 11